BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro

Cancer Biology and Therapy

Volumn 11, Issue 3, 2011, Pages 349-357

  Scherzed, Agmal ^a   Hackenberg, Stephan ^a   Froelich, Katrin ^a   Kessler, Michael ^a   Koehler, Christian ^a   Hagen, Rudolf ^a   Radeloff, Andreas ^a   Friehs, Gudrun ^a   Kleinsasser, Norbert ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

BMSC; Bone marrow derived mesenchymal stem cells; Cytokines; HNSCC; Paclitaxel; Squamous carcinoma cell line

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYTOKINE; PACLITAXEL; PROPIDIUM IODIDE;

ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; LYMPHOID PROGENITOR CELL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BONE MARROW CELLS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MESENCHYMAL STEM CELLS; PACLITAXEL;

EID: 79951548240     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.3.14179     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108.
2. Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009; 8:676-82.
3. Marron M, Boffetta P, Zhang ZF, Zaridze D, Wünsch-Filho V, Winn DM, et al. Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2009; 39:182-96.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-14.
5. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83:1797-805.
6. Khayat D, Antoine EC, Coeffic D. Taxol in the management of cancers of the breast and the ovary. Cancer Invest 2000; 18:242-60. (Pubitemid 30164153)
7. Tishler RB, Busse PM, Norris CM Jr, Rossi R, Poulin M, Thornhill L, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 1999; 43:1001-8. (Pubitemid 29144786)
8. Xiang J, Tang J, Song C, Yang Z, Hirst DG, Zheng QJ, et al. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 2009; 11:516-26.
9. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2010; 121:293-300.
10. Pathak S. Organ- and tissue-specific stem cells and carcinogenesis. Anticancer Res 2002; 22:1353-6. (Pubitemid 34839137)
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7. (Pubitemid 29282067)
12. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221-8. (Pubitemid 29377293)
13. Malek S, Kaplan E, Wang JF, Ke Q, Rana JS, Chen Y, et al. Successful implantation of intravenously administered stem cells correlates with severity of inflammation in murine myocarditis. Pflugers Arch 2006; 452:268-75. (Pubitemid 43781335)
14. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96:149-56. (Pubitemid 40575915)
15. Kaplan RN, Psaila B. Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 2007; 13:72-81. (Pubitemid 46201791)
16. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-41. (Pubitemid 30240545)
17. Huang Q, Liu XZ, Kang CS, Wang GX, Zhong Y, Pu PY. The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells. Cancer Gene Ther 2009; 17:192-202.
18. Zenner HP, Lehner W, Herrmann IF. Establishment of carcinoma cell lines from larynx and submandibular gland. Arch Otorhinolaryngol 1979; 225:269-77. (Pubitemid 10182531)
19. Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972; 29:117-21.
20. Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 2004; 14:311-24. (Pubitemid 39179200)
21. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology 1994; 134:277-86. (Pubitemid 24021999)
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63. (Pubitemid 14203433)
23. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, et al. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clin Cancer Res 2009; 15:7175-85.
24. Gatti L, Zunio F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005; 111:127-48.
25. Arlt A, Vorndamm J, Müerköster S, Yu H, Schmidt WE, Fölsch UR, et al. Autocrine production of interleukin 1beta confers constitutive nuclear factorkappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002; 62:919-26.
26. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64:1331-7. (Pubitemid 38235601)
27. Tsang WP, Kong SK, Kwok TT. Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells. Oncol Rep 2006; 16:789-93.
28. Dhawan V, Swaffar DS. A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha. Anticancer Drugs 1999; 10:397-404.
29. Kemp KC, Hows J, Donaldson C. Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma 2005; 46:1531-44. (Pubitemid 41700985)
30. Wang Y, Wang M, Abarbanell AM, Weil BR, Herrmann JL, Tan J, et al. MEK mediates the novel cross talk between TNFR2 and TGF-EGFR in enhancing vascular endothelial growth factor (VEGF) secretion from human mesenchymal stem cells. Surgery 2009; 146:198-205.
31. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007; 180:263-83.
32. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69:329-37.
33. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159:2212-21. (Pubitemid 127681011)
34. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20:5991-6000. (Pubitemid 32955041)
35. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Löffler D, Koczan D, et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103:242-51. (Pubitemid 38029945)
36. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-63. (Pubitemid 47525152)
37. Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004; 22:415-27. (Pubitemid 38736625)
38. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration and body distribution. Circulation 2003; 108:863-8. (Pubitemid 37022130)
39. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006; 82:1060-6. (Pubitemid 44632122)
40. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5:309-13. (Pubitemid 29124367)
41. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62:3603-8. (Pubitemid 34728832)